Table 2.
Patient baseline characteristics
| Number | Study | Drugs, Doses (μg), Regimen, Device | No of patients | Age means (SD) | Male (%) | Current smoker (%) | Postbronchodilator FEV1, % Predicted (SD) | Moderate/severe COPD exacerbation in previous 12 months, n (%) 0 | Moderate/severe COPD exacerbation in previous 12 months, n (%) 1 | Moderate/severe COPD exacerbation in previous 12 months, n (%) ≥ 2 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | TRILOGY Singh, 2016 | BDP/FOR/GLY (100/6/12.5) bid MDI | 687 | 63.3 (7.9) | 74 | 47 | 36.9 (8.4) | NA | NA | NA |
| BDP/FOR (100/6) bid MDI | 680 | 63.8 (8.2) | 77 | 47 | 36.2 (8.6) | NA | NA | NA | ||
| 2 | FULFIL Lipson,2017 | FF/UMEC/VI (100/62.5/25) od DPI | 911 | 64.2 (8.56) | 74 | 44 | 45.5 (12.97) | 34 | 28 | 38 |
| BUD/FOR (400/12) bid DPI | 899 | 63.7 (8.71) | 74 | 44 | 45.1 (13.64) | 35 | 28 | 37 | ||
| 3 | IMPACT Lipson,2018 | FF/UMEC/VI (100/62.5/25) od DPI | 4151 | 65.3 (8.2) | 67 | 35 | 45.7 (15.0) | < 1 | 45 | 55 |
| FF/VI (100/25) od DPI | 4134 | 65.3 (8.3) | 66 | 34 | 45.5 (14.8) | < 1 | 46 | 54 | ||
| UMEC/VI (62.5/25) od DPI | 2070 | 65.2 (8.3) | 66 | 35 | 45.4 (14.7) | < 1 | 45 | 55 | ||
| 4 | KRONOS Ferguson,2018 | BUD/GLY/FOR (320/18/9.6) bid MDI | 639 | 64.9 (7.8) | 72 | 40.1 | 50.2 (14.3) | 73.4 | 19.6 | 7 |
| GLY/FOR (18/9.6) bid MDI | 625 | 65.1 (7.7) | 68.8 | 41.1 | 50.2 (13.8) | 75.7 | 17.3 | 7 | ||
| BUD/FOR (320/9.6) bid MDI | 314 | 65.2 (7.2) | 71.3 | 36.6 | 50 (14) | 74.8 | 19.4 | 5.7 | ||
| 5 | TRIBUTE Papi,2018 | BDP/FOR/GLY (100/6/10) bid MDI | 764 | 64.4 (7.7) | 72 | 46 | 36.4 (8.0) | NA | 80 | 20 |
| IND/GLY (85/43) od DPI | 768 | 64.5 (7.7) | 72 | 43 | 36.4 (8.1) | NA | 82 | 18 | ||
| 6 | ETHOS Rabe,2020 | BUD/GLY/FOR (320/18/9.6) bid MDI | 2144 | 64.6 (7.6) | 59 | 42.6 | 43.6 (10.3) | 0.1 | 44 | 55.9 |
| BUD/GLY/FOR (160/18/9.6) bid MDI | 2124 | 64.6 (7.6) | 61.2 | 40.8 | 43.1 (10.4) | 0.1 | 43.9 | 56 | ||
| BUD/FOR (320/9.6) bid MDI | 2136 | 64.6 (7.6) | 60 | 40.5 | 43.4 (10.4) | 0.1 | 42.8 | 57.1 | ||
| GLY/FOR (18/9.6) bid MDI | 2125 | 64.8 (7.6) | 58.7 | 40.4 | 43.5 (10.2) | 0.1 | 42.8 | 57.1 |
BDP/FOR/GLY: beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide; BUD/GLY/FOR: budesonide/glycopyrronium bromide/formoterol fumarate; FF/UMEC/VI: fluticasone furoate/umeclidinium/vilanterol; BDP/FOR: beclomethasone dipropionate/formoterol fumarate; BUD/FOR: budesonide/formoterol fumarate; UMEC/VI: umeclidinium bromide/vilanterol; GLY/FOR: glycopyrronium bromide/formoterol fumarate; IND/GLY: indacaterol/glycopyrronium bromide; OD: once daily; BID: twice daily; MDI: metered-dose inhaler formulation; DPI: dry powder inhaler formulation; SD: Standard deviation; NA: Not applicable